

Global Cancer Profiling Market Assessment, By Biomarker Type [Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers], By Technology [Immunoassays, Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Microarray, Spectroscopic Method, Others], By Cancer Type [Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Other Cancer], By Application [Clinical Application, Research Application], By End-user [Hospital Associated Diagnostic Laboratories, Diagnostic Centers, Cancer Research Institutes, Others], By Region, Opportunities and Forecast, 2017-2031F

Market Report | 2024-04-19 | 217 pages | Market Xcel - Markets and Data

AVAILABLE LICENSES:

- Single User License \$4500.00
- Multi-User/Corporate Licence \$5700.00
- Custom Research License \$8200.00

Report description:

Global cancer profiling market size was valued at USD 11.16 billion in 2023, expected to reach USD 22.53 billion in 2031, with a CAGR of 9.18% for the forecast period between 2024 and 2031F. The global cancer profiling market is highly dynamic, fostering many market players. The market is expected to grow exponentially due to the increasing number of cancer cases around the world.

As per WHO, cancer is the second leading cause of death globally. The surge in the prevalence of cancer can be attributed to inherited mutations, alcohol and tobacco consumption, hormonal and lifestyle changes, and carcinogenic microbial infections,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

which play an important role in driving the global cancer profiling market. Owing to this fact, healthcare professionals and market players are focused on developing more advanced solutions like cancer profiling for precise cancer diagnosis to reduce the cancer burden.

Tumor profiling enables healthcare professionals to develop personalized therapy based on unique genetic profiles of individuals, leading to highly effective therapeutic outcomes. The market for cancer profiling is expanding due to the use of technology such as artificial intelligence and machine learning for cancer diagnosis and prediction.

Growing industry partnerships, the introduction of cutting-edge products, and government programs to promote cancer screening are expected to fuel market expansion throughout the projected period. In July 2023, the pioneer in diagnostic information services, Quest Diagnostics, announced the introduction of a new prostate cancer biomarker test via its subspecialty pathology company, AmeriPath, in association with Envision Sciences. The goal of the new tissue-based test service is to assist in meeting the urgent clinical demand for diagnostics that can distinguish between aggressive and less aggressive cases of prostate cancer in men.

Increasing Prevalence of Cancer

Cancer is one of the leading causes of death in developed and developing countries. Exposure to radiation, alcohol and tobacco consumption, and lifestyle changes are the major contributors to the increasing number of cancer patients globally. The market for cancer profiling is expected to grow due to the development of precise diagnostics that can be used to profile and treat cancer. In this case, cancer profiling becomes essential for offering customized treatment alternatives, which further propels the growth of global cancer profiling market. As per WHO, newly diagnosed cancer cases are expected to increase to around 21.62 million with a growth rate of 12.1% by 2025. Among all cases, breast cancer is the world's most prevalent cancer. Breast cancer ranks first among all types of cancer accounting for 12% share.

Growing Preference to Personalized Therapies

Improved outcomes in cancer treatments can be achieved by personalized therapy. Tumor or cancer profiling is the preliminary step in the development of personalized therapy, which drives innovation and growth in the market. This personalized approach, guided by advancements in genomic technologies, increases treatment efficacy, reduces adverse effects, and improves patient outcomes. The integration of cancer profiling in clinical trial design, increasing popularity of immunotherapy, and supportive government initiatives contribute to the growing adoption of personalized medicine in cancer care.

In March 2023, Artera invested USD 90 million to customize treatment for prostate cancer. The business will use the money to distribute its ArteraAI Prostate Test and create tests that would enable customized treatment plans for various cancers. By examining the patient's clinical information and biopsy images, Artera's multimodal AI-powered test for prostate cancer patients, known as the ArteraAI Prostate Test, assists in forecasting the possible advantages of treatment and the patient's prognosis.

Government Initiatives

Governments around the globe are actively pushing cancer screening and therapies through awareness campaigns, which is driving growth in the worldwide cancer profiling market. The government is funding research projects targeting cancer diagnosis techniques. In March 2023, the United States government invested USD 394.5 million in three CDC programs, National Comprehensive Cancer Control Program, National Breast and Cervical Cancer Early Detection Programs, and the Colorectal Cancer Control Program to reduce the cancer burden of the country. In January 2023, to decrease the incidence of breast cancer in the United Kingdom, government announced investment of EUR 10 million to build 29 new breast cancer screening facilities.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the global cancer profiling market. Cancer patients were amongst the most vulnerable populations. Although cancer screening is essential for controlling and prevention of cancer, a large number of screenings were canceled or postponed as a result of the COVID-19 pandemic, affecting a large number of patients for access to necessary medical care. There was large scale impact on patients, medical professionals, and health system from the disruption caused by COVID-19 on cancer profiling market. According to a paper published in SAGE in June 2022, between 2019 and 2020, there was a 44% decrease in breast cancer screening mammography.

Key Players Landscape and Outlook

Market players are employing a range of strategies to increase their range of solutions offered while giving their customers access to a wide selection of innovative and cutting-edge products. Additionally, companies are expanding the range of diagnostic

services they offer to capture a large portion of the market. Many major industry players are using both organic and inorganic growth techniques, like partnerships, mergers and acquisitions, and launch of new products, to strengthen their position in the global market.

In April 2023, Agilent Technologies introduced a CGP test intended for somatic variant profiling. The technique, known as Agilent SureSelect Cancer CGP, decreases hands-on time and increases workflow efficiency to enable scientists to profile a larger variety of tumor samples. The pan-cancer test was developed based on a next-generation sequencing (NGS) panel of 679 genes compiled from cancer databases and research collaborations.

Table of Contents:

1. Research Methodology
2. Project Scope & Definitions
3. Impact of COVID-19 on Global Cancer Profiling Market
4. Executive Summary
5. Global Cancer Profiling Market Outlook, 2017-2031F
 - 5.1 Market Size & Forecast
 - 5.1.1 By Value
 - 5.1.2 By Volume
 - 5.2 By Biomarker Type
 - 5.2.1 Genetic Biomarkers
 - 5.2.2 Protein Biomarkers
 - 5.2.3 Other Cancer Biomarkers
 - 5.3 By Technology
 - 5.3.1 Immunoassays
 - 5.3.2 Next-generation Sequencing (NGS)
 - 5.3.3 Polymerase Chain Reaction (PCR)
 - 5.3.4 In Situ Hybridization (ISH)
 - 5.3.5 Microarrays
 - 5.3.6 Spectroscopic Method
 - 5.3.7 Others
 - 5.4 By Cancer Type
 - 5.4.1 Breast Cancer
 - 5.4.2 Lung Cancer
 - 5.4.3 Colorectal Cancer
 - 5.4.4 Melanoma
 - 5.4.5 Blood Cancer
 - 5.4.6 Prostate Cancer
 - 5.4.7 Ovarian Cancer
 - 5.4.8 Stomach Cancer
 - 5.4.9 Liver Cancer
 - 5.4.10 Other Cancer
 - 5.5 By Application
 - 5.5.1 Clinical Application
 - 5.5.1.1 Diagnostics
 - 5.5.1.2 Prognostics
 - 5.5.1.3 Monitoring and Treatment
 - 5.5.1.4 Screening
 - 5.5.2 Research Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.5.2.1 Biomarker Discovery
- 5.5.2.2 Drug Development
- 5.6 By End-user
 - 5.6.1 Hospital Associated Diagnostic Laboratories
 - 5.6.2 Diagnostic Centers
 - 5.6.3 Cancer Research Institutes
 - 5.6.4 Others
- 5.7 By Region
 - 5.7.1 North America
 - 5.7.2 Europe
 - 5.7.3 Asia-Pacific
 - 5.7.4 South America
 - 5.7.5 Middle East & Africa
- 5.8 By Company Market Share (%), 2022
- 7. Global Cancer Profiling Market Outlook, 2017-2031F
 - 7.1 North America
 - 7.1.1 Market Size & Forecast
 - 7.1.1.1 By Value
 - 7.1.1.2 By Volume
 - 7.1.2 By Biomarker Type
 - 7.1.2.1 Genetic Biomarkers
 - 7.1.2.2 Protein Biomarkers
 - 7.1.2.3 Other Cancer Biomarkers
 - 7.1.3 By Technology
 - 7.1.2.1 Immunoassays
 - 7.1.2.2 Next-generation Sequencing (NGS)
 - 7.1.2.3 Polymerase Chain Reaction (PCR)
 - 7.1.2.4 In Situ Hybridization (ISH)
 - 7.1.2.5 Microarrays
 - 7.1.2.6 Spectroscopic Method
 - 7.1.2.7 Others
 - 7.1.3 By Cancer Type
 - 7.1.3.1 Breast Cancer
 - 7.1.3.2 Lung Cancer
 - 7.1.3.3 Colorectal Cancer
 - 7.1.3.4 Melanoma
 - 7.1.3.5 Blood Cancer
 - 7.1.3.6 Prostate Cancer
 - 7.1.3.7 Ovarian Cancer
 - 7.1.3.8 Stomach Cancer
 - 7.1.3.9 Liver Cancer
 - 7.1.3.10 Other Cancer
 - 7.1.4 By Application
 - 7.1.4.1 Clinical Application
 - 7.1.4.1.1 Diagnostics
 - 7.1.4.1.2 Prognostics
 - 7.1.4.1.3 Monitoring and Treatment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.4.1.4□Screening
- 7.1.4.2□Research Application
- 7.1.4.2.1□Biomarker Discovery
- 7.1.4.2.2□Drug Development
- 7.1.4.□By End-user
- 7.1.4.1.□Hospital Associated Diagnostic Laboratories
- 7.1.4.2.□Diagnostic Centers
- 7.1.4.3.□Cancer Research Institutes
- 7.1.4.4.□Others
- 7.1.5.□United States*
- 7.1.5.1.□Market Size & Forecast
- 7.1.5.1.1.□By Value
- 7.1.5.1.2.□By Volume
- 7.1.4.1□By Biomarker Type
- 7.1.5.1.3.□Genetic Biomarkers
- 7.1.5.1.4.□Protein Biomarkers
- 7.1.5.1.5.□Other Cancer Biomarkers
- 7.1.5.2.□By Technology
- 7.1.4.2.1□Immunoassays
- 7.1.4.2.2□Next-generation Sequencing (NGS)
- 7.1.4.2.3□Polymerase Chain Reaction (PCR)
- 7.1.4.2.4□In Situ Hybridization (ISH)
- 7.1.4.2.5□Microarrays
- 7.1.4.2.6□Spectroscopic Method
- 7.1.4.2.7□Others
- 7.1.4.3□By Cancer Type
- 7.1.4.3.1□Breast Cancer
- 7.1.4.3.2□Lung Cancer
- 7.1.4.3.3□Colorectal Cancer
- 7.1.4.3.4□Melanoma
- 7.1.4.3.5□Blood Cancer
- 7.1.4.3.6□Prostate Cancer
- 7.1.4.3.7□Ovarian Cancer
- 7.1.4.3.8□Stomach Cancer
- 7.1.4.3.9□Liver Cancer
- 7.1.4.3.10□Other Cancer
- 7.1.4.4□By Application
- 7.1.4.4.1□Clinical Application
- 7.1.4.4.1.1□Diagnostics
- 7.1.4.4.1.2□Prognostics
- 7.1.4.4.1.3□Monitoring and Treatment
- 7.1.4.4.1.4□Screening
- 7.1.4.4.2□Research Application
- 7.1.4.4.2.1□Biomarker Discovery
- 7.1.4.4.2.2□Drug Development
- 7.1.4.5□By End-user
- 7.1.4.5.1□Hospital Associated Diagnostic Laboratories

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.4.5.2□Diagnostic Centers
- 7.1.4.5.3□Cancer Research Institutes
- 7.1.4.5.4□Others
- 7.1.5□Canada
- 7.1.6□Mexico
- *All segments will be provided for all regions and countries covered
- 7.2□Europe
 - 7.2.2□Germany
 - 7.2.3□France
 - 7.2.4□Italy
 - 7.2.5□United Kingdom
 - 7.2.6□Russia
 - 7.2.7□Netherlands
 - 7.2.8□Spain
 - 7.2.9□Turkey
 - 7.2.10□Poland
- 7.3□South America
 - 7.3.2□Brazil
 - 7.3.3□Argentina
- 7.4□Asia-Pacific
 - 7.4.2□India
 - 7.4.3□China
 - 7.4.4□Japan
 - 7.4.5□Australia
 - 7.4.6□Vietnam
 - 7.4.7□South Korea
 - 7.4.8□Indonesia
 - 7.4.9□Philippines
- 7.5□Middle East and Africa
 - 7.5.2□Saudi Arabia
 - 7.5.3□UAE
 - 7.5.4□South Africa
- 8□Market Mapping, 2023
 - 8.1□By Biomarker Type
 - 8.2□By Technology
 - 8.3□By Cancer Type
 - 8.4□By Application
 - 8.5□By End-user
 - 8.6□By Region
- 9□Macro Environment and Industry Structure
 - 9.1□Supply Demand Analysis
 - 9.2□Import Export Analysis - Volume and Value
 - 9.3□Supply/Value Chain Analysis
 - 9.4□PESTEL Analysis
 - 9.4.2□Political Factors
 - 9.4.3□Economic System
 - 9.4.4□Social Implications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.5□Technological Advancements
- 9.4.6□Environmental Impacts
- 9.4.7□Legal Compliances and Regulatory Policies (Statutory Bodies Included)
- 9.5□Porter's Five Forces Analysis
- 9.5.2□Supplier Power
- 9.5.3□Buyer Power
- 9.5.4□Substitution Threat
- 9.5.5□Threat from New Entrant
- 9.5.6□Competitive Rivalry
- 10□Market Dynamics
- 10.1□Growth Drivers
- 10.2□Growth Inhibitors (Challenges, Restraints)
- 11□Regulatory Framework and Innovation
- 11.1□Clinical Trials
- 11.2□Patent Landscape
- 11.3□Regulatory Approvals
- 11.4□Innovations/Emerging Technologies
- 12□Key Players Landscape
- 12.1□Competition Matrix of Top Five Market Leaders
- 12.2□Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
- 12.3□Mergers and Acquisitions/Joint Ventures (If Applicable)
- 12.4□SWOT Analysis (For Five Market Players)
- 12.5□Patent Analysis (If Applicable)
- 13□Pricing Analysis
- 14□Case Studies
- 15□Key Players Outlook
- 15.1□Illumina, Inc.
- 15.1.2□Company Details
- 15.1.3□Key Management Personnel
- 15.1.4□Products & Services
- 15.1.5□Financials (As reported)
- 15.1.6□Key Market Focus & Geographical Presence
- 15.1.7□Recent Developments
- 15.2□QIAGEN NV
- 15.3□NeoGenomics Laboratories, Inc.
- 15.4□HTG Molecular Diagnostics, Inc.
- 15.5□Genomic Health Inc.
- 15.6□Caris Life Sciences
- 15.7□Helomics Corporation
- 15.8□NanoString Technologies, Inc.
- 15.9□Sysmex Corporation
- 15.10□Ribomed Biotechnologies, Inc.
- 15.11□Guardant Health, Inc.
- 15.12□Foundation Medicine
- 15.13□Roche Holding AG
- 15.14□GenScript Biotech Corporation
- 15.15□Tempus Labs, Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

16□Strategic Recommendations

17□About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Cancer Profiling Market Assessment, By Biomarker Type [Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers], By Technology [Immunoassays, Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Microarray, Spectroscopic Method, Others], By Cancer Type [Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Other Cancer], By Application [Clinical Application, Research Application], By End-user [Hospital Associated Diagnostic Laboratories, Diagnostic Centers, Cancer Research Institutes, Others], By Region, Opportunities and Forecast, 2017-2031F

Market Report | 2024-04-19 | 217 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Muti-User/Corporate Licence	\$5700.00
	Custom Research License	\$8200.00
		VAT
		Total

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.
☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<div><div></div></div>